Company Overview and News
Core Exploration Ltd (ASX:CXO) has been rated a speculative buy with a price target of 6.5 cents per share by Perth-based RM Research.
Core Exploration Ltd (ASX:CXO) managing director Stephen Biggins speaks with Proactive Investors about the key Finniss Lithium Project.
Core Exploration Ltd (ASX:CXO) has discovered significant extensions to the Grants Lithium Deposit, part of its Finniss Lithium Project near Darwin in the Northern Territory.
This article was first published on Trend Investing on May 4; therefore all data is as of that date.
URA CLA CCZ SRHYY KBGCF CYDVF LMRMF PCRCF PLM.RT HNCKF SNNAF ZEYYF WML POR SQM AVLNF BXTMF AIS.H POM AYR KBBRF ABE FTMDF MNIKF GBLEF GLCNF TON NMKEF POS DNI MGXMF DJIFF GME CRECF AQR LMR NGPHF CDNMD LEMIF CDNMF GLK WWR AEOMF KATFF KNL NTTHF ECORF URI CNJ TSLA FCSMF HLPCF CUC AJM WSCRF GRXXF SIE TNTMF CXO SAV HAV LIACF MUM URLNF NI HIG URRE PFFOF TAKRF ABEPF PSDNF STLHF SYA GPHOF LLG APMFD WMLLF APMFF NSRC CYLYF NGZ RNX.WT GXY KAT PLU VNCKF AMLM CSSQF XTM AVL ALB FMS LACDF HBNRF CZI ZENYF AUZ RNX PLUUF RNKLF DMNKF NMX SYR GLKIF EMH OROCF MSMGD LAC MSMGF PLS FT CARCF FTI.WI FMC ZEN USCFF DJI SYAAF PDDTF PLM AVLIF CYP NSRCF MGPHF MCCBF LNZCF ORE AVZ
Lithium market news: Joe Lowry significantly raised his new lithium demand forecast to ~800K MT LCE in 2025. Indian State-owned firms mandated to acquire overseas lithium and cobalt.
NI LIT CXO SAV LAXXF LIACF CYDVF AGY PFFOF WML POR ABEPF SQM MLNLF AVLNF AIS.H KDR SYA STLHF WMLLF LNRDY HMGLF PEMIF ABE NGZ LMMFF GXY LRS MNIKF PLU HNR AMLM 9984 AVL ALB DMNXF MALRY EEYMF SFTBF MIN NMKEF ARYMF LKE DDXFF MGXMF PLUUF DJIFF NMX PSC EMH CRECF ERPNF SFTBY PLS NNO DJI PDDTF NTTHF NNOMF CYP MALRF ORE AVZ AJM
Core Exploration Ltd's (ASX:CXO) managing director, Stephen Biggins, presented to investors at Proactive's CEO Sessions this week in Melbourne and Sydney.
Core Exploration Ltd (ASX:CXO) has delivered the pre-feasibility study (PFS) for the Grants Lithium Deposit, a key component of its Finniss Lithium Project, near Darwin in the Northern Territory.
Core Exploration Ltd (ASX:CXO) has commenced a drilling program to expand the lithium resource at its Finniss Lithium Project in the Northern Territory.
Lithium spot and contract price news - Spot prices very slightly down and contract prices rising.
LIT CXO SAV LAXXF LIACF CYDVF AGY PFFOF WML POR ABEPF SQM MLNLF AVLNF AIS.H KDR SYA STLHF WP WMLLF LNRDY HMGLF PEMIF ABE NGZ VLKAF LMMFF GXY LRS MNIKF PLU HNR AMLM AVL ALB DMNXF MALRY EEYMF MIN NMKEF ARYMF LKE DDXFF MGXMF PLUUF DJIFF NMX EMH CRECF PSC ERPNF PLS NNO DJI PDDTF WAL NTTHF NNOMF AVLIF CYP MALRF ORE AVZ AJM
Core Exploration Ltd (ASX:CXO) has received a maiden resource estimate for the BP33 lithium deposit of 1.4 million tonnes grading 1.4% lithium oxide.
Core Exploration Ltd (ASX:CXO) director, Stephen Biggins, has purchased 188,680 shares for $10,000 by participating in the company’s share purchase plan.
Core Exploration Ltd (ASX:CXO) has consistently delivered positive news in 2018 and just this week shareholders were encouraged by additional financial support from a key Chinese investor.
Core Exploration Ltd (ASX:CXO) has doubled the indicated lithium resource at the Grants lithium deposit within its Finniss Lithium Project in the Northern Territory.
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
Silicon Investor Message Boards
This table lists all message boards related to ASX:CXO / CORE EXPLORATION LIMITED on message board site Silicon Investor.
|CXO Colorado Resources|